Published in Ophthalmol Ther on June 05, 2017
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 40.02
The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol (2006) 25.47
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89
The L-arginine-nitric oxide pathway. N Engl J Med (1993) 14.38
Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol (2004) 13.78
Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature (1990) 7.23
Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol (1991) 5.82
Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology (2014) 5.42
Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol (1981) 5.09
Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A (1977) 4.90
Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A (2001) 3.88
Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci (2011) 3.19
Natural history of open-angle glaucoma. Ophthalmology (2009) 2.99
Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology (2000) 2.75
Nitric oxide: mediator, murderer, and medicine. Lancet (1994) 2.74
Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology (1999) 2.74
VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol (1998) 2.71
Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol (1995) 2.67
Intraocular pressure in an American community. The Beaver Dam Eye Study. Invest Ophthalmol Vis Sci (1992) 2.55
Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci U S A (1982) 2.45
Endothelial cells as mediators of vasodilation of arteries. J Cardiovasc Pharmacol (1984) 2.24
Nitric oxide modulates microvascular permeability. Am J Physiol (1992) 2.21
The histology of human glaucoma cupping and optic nerve damage: clinicopathologic correlation in 21 eyes. Ophthalmology (1979) 1.97
Shear stress affects the intracellular distribution of eNOS: direct demonstration by a novel in vivo technique. Blood (2005) 1.92
The changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endothelium. Exp Eye Res (2008) 1.77
The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care (2003) 1.63
Collaborative normal tension glaucoma study. Curr Opin Ophthalmol (2003) 1.60
Aqueous humor dynamics: a review. Open Ophthalmol J (2010) 1.55
Purification and reconstitution of the high-conductance, calcium-activated potassium channel from tracheal smooth muscle. J Biol Chem (1994) 1.54
Constitutive eNOS-derived nitric oxide is a determinant of endothelial junctional integrity. Am J Physiol Lung Cell Mol Physiol (2005) 1.54
VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun (1998) 1.51
eNOS, a pressure-dependent regulator of intraocular pressure. Invest Ophthalmol Vis Sci (2011) 1.38
Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with sex and postmenopausal hormone use. Invest Ophthalmol Vis Sci (2009) 1.36
Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Invest Ophthalmol Vis Sci (1995) 1.33
The molecule of the year. Science (1992) 1.32
Evaluation of retinal nerve fiber layer progression in glaucoma a prospective analysis with neuroretinal rim and visual field progression. Ophthalmology (2011) 1.26
Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma. Br J Ophthalmol (2004) 1.26
Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. Hypertension (1998) 1.26
Nitric oxide in vascular biology. J Thromb Haemost (2003) 1.23
Endothelial dysfunction in glaucoma. Acta Ophthalmol (2008) 1.20
Peripheral endothelial dysfunction in normal pressure glaucoma. Invest Ophthalmol Vis Sci (1999) 1.16
Schlemm's canal endothelia, lymphatic, or blood vasculature? J Glaucoma (2007) 1.14
Epidemiology of intraocular pressure in a population screened for glaucoma. Br J Ophthalmol (1987) 1.14
Biomechanics of Schlemm's canal endothelial cells: influence on F-actin architecture. Biophys J (2004) 1.13
Alterations of ocular nitric oxide synthase in human glaucoma. Invest Ophthalmol Vis Sci (1995) 1.10
Aspects of the development of Schlemm's canal. Exp Eye Res (1992) 1.08
Comparison of methods to evaluate the optic nerve head and nerve fiber layer for glaucomatous change. Am J Ophthalmol (1996) 1.05
Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys. Exp Eye Res (1994) 1.05
NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. Am J Physiol Cell Physiol (2008) 1.02
The effect of systemic nitric oxide-synthase inhibition on ocular fundus pulsations in man. Exp Eye Res (1997) 1.00
L-arginine-derived nitric oxide: a major determinant of uveal blood flow. Exp Eye Res (1993) 0.98
Nitric oxide/guanylate cyclase pathways and flow in anterior segment perfusion. Graefes Arch Clin Exp Ophthalmol (2002) 0.97
Decreased nitric oxide production in primary open-angle glaucoma. Eur J Ophthalmol (2002) 0.96
Proteins secreted by human trabecular cells. Glucocorticoid and other effects. Invest Ophthalmol Vis Sci (1989) 0.95
Differential regulation of inducible nitric oxide synthase by fibroblast growth factors and transforming growth factor beta in bovine retinal pigmented epithelial cells: inverse correlation with cellular proliferation. Proc Natl Acad Sci U S A (1993) 0.94
The structure of the trabecular meshwork, its connections to the ciliary muscle, and the effect of pilocarpine on outflow facility in mice. Invest Ophthalmol Vis Sci (2014) 0.93
Risk factors for open-angle glaucoma: the Barbados Eye Study. Arch Ophthalmol (1996) 0.92
Concentration-related effects of nitric oxide and endothelin-1 on human trabecular meshwork cell contractility. Exp Eye Res (2013) 0.92
Trabecular cells express the TGF-beta 2 gene and secrete the cytokine. Exp Eye Res (1994) 0.91
Role of nitric oxide in murine conventional outflow physiology. Am J Physiol Cell Physiol (2015) 0.91
Characterization of soluble guanylate cyclase in NO-induced increases in aqueous humor outflow facility and in the trabecular meshwork. Invest Ophthalmol Vis Sci (2008) 0.90
Elevated intraocular pressure and pseudoexfoliation of the lens capsule as risk factors for chronic open-angle glaucoma. A population-based five-year follow-up study. Acta Ophthalmol (Copenh) (1993) 0.90
Ocular haemodynamics and nitric oxide in normal pressure glaucoma. Acta Ophthalmol Scand Suppl (2000) 0.88
Endothelin-1, nitric oxide, and glutamate in the normal and glaucomatous dog eye. Vet Ophthalmol (2007) 0.87
Altered endothelin-1 vasoreactivity in patients with untreated normal-pressure glaucoma. Invest Ophthalmol Vis Sci (2006) 0.87
Effect of isosorbide mononitrate on the human optic nerve and choroidal circulations. Br J Ophthalmol (1999) 0.87
Nitric oxide-mediated retinal arteriolar and arterial dilatation induced by substance P. Invest Ophthalmol Vis Sci (1993) 0.86
Endothelin antagonism as an active principle for glaucoma therapy. Br J Pharmacol (2011) 0.85
Enhanced expression of nitric oxide synthase by rat retina following pterygopalatine parasympathetic denervation. Brain Res (1993) 0.84
A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol (2014) 0.83
Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care (2010) 0.82
Natural history of intraocular pressure in the early manifest glaucoma trial: A 6-year follow-up. Arch Ophthalmol (2010) 0.82
Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. Ophthalmology (2016) 0.81
Shear stress-triggered nitric oxide release from Schlemm's canal cells. Invest Ophthalmol Vis Sci (2014) 0.79
Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study. Am J Ophthalmol (2016) 0.78
Correlation between the progression of optic disc and visual field changes in glaucoma. Curr Eye Res (1996) 0.77
Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects. Adv Ther (2015) 0.77
Enhanced oxygen saturation in optic nerve head of non-human primate eyes following the intravitreal injection of NCX 434, an innovative nitric oxide-donating glucocorticoid. J Ocul Pharmacol Ther (2011) 0.76
Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study. Adv Ther (2016) 0.76
Nitroglycerin and Nitric Oxide--A Rondo of Themes in Cardiovascular Therapeutics. N Engl J Med (2015) 0.75